Search

Your search keyword '"Engels K"' showing total 222 results
Start Over Author "Engels K" Language english
222 results on '"Engels K"'

1. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Author

Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B.V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W.D., von Minckwitz, G., Thomalla, J., Kümmel, S., Rautenberg, B., Fasching, P.A., Weber, K., Rhiem, K., Denkert, C., and Schneeweiss, A.

Published
2019
Full Text
View/download PDF

2. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

Author

Loibl, S., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., Wiebringhaus, H., Kümmel, S., Warm, M., Paepke, S., Just, M., Hanusch, C., Hackmann, J., Blohmer, J.-U., Clemens, M., Dan Costa, S., Gerber, B., Engels, K., Nekljudova, V., von Minckwitz, G., and Untch, M.

Published
2017
Full Text
View/download PDF

9. VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection

Author

Engels, K., Bois, A. du, Harter, P., Fisseler-Eckhoff, A., Kommoss, F., Stauber, R., Kaufmann, M., Nekljudova, V., and Loibl, S.

Subjects
Ovarian cancer -- Prognosis, Ovarian cancer -- Genetic aspects, Ovarian cancer -- Diagnosis, Gene expression -- Research, Gene expression -- Physiological aspects, Immunohistochemistry -- Usage, Gynecology, Operative -- Patient outcomes, Health
Published
2009

21. Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288]

Author

Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B.V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W.D., von Minckwitz, G., Thomalla, J., Kümmel, S., Rautenberg, B., Fasching, P.A., Weber, K., Rhiem, K., Denkert, C., and Schneeweiss, A.

Published
2022
Full Text
View/download PDF

22. 94P Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC)

Author

Reinisch, M., Blohmer, J-U., Link, T., Just, M., Untch, M., Stötzer, O., Fasching, P.A., Schneeweiss, A., Wimberger, P., Seiler, S., Huober, J., Thill, M., Jackisch, C., Rhiem, K., Solbach, C., Hanusch, C., Denkert, C., Engels, K., Nekljudova, V., and Loibl, S.

Published
2022
Full Text
View/download PDF

26. Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy : A metaanalysis of 3771 patients

Author

Schneeweiss, A, Schmitt, W, Denkert, C, Loibl, S, Darb-Esfahani, S, von Minckwitz, G, Kümmel, S, Pfitzner, B, Hanusch, C, Lederer, B, Engels, K, Hartmann, A, Furlanetto, J, Blohmer, J-U, Klauschen, F, Untch, M, Jakisch, C, Weber, K, Ingold Heppner, B, and Huober, J

Subjects
Medizin
Published
2017

27. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer : a subanalysis of data from the randomized phase III GeparSepto trial

Author

Loibl, S, Jackisch, C, Schneeweiss, A, Schmatloch, S, Aktas, B, Denkert, C, Wiebringhaus, H, Kümmel, S, Warm, M, Paepke, S, Just, M, Hanusch, C, Hackmann, J, Blohmer, J-U, Clemens, M, Costa, S Dan, Gerber, B, Engels, K, Nekljudova, V, von Minckwitz, G, Untch, M, and investigators of the German Breast Group (GBG) and the Arbeitsgemeinschaft Gynäkologische Onkologie--Breast (AGO-B) study groups.

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Paclitaxel, Receptor, ErbB-2, medicine.medical_treatment, Medizin, Breast Neoplasms, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Trastuzumab, Internal medicine, Albumins, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Anthracyclines, skin and connective tissue diseases, neoplasms, Neoadjuvant therapy, Aged, Epirubicin, Neoplasm Staging, Chemotherapy, business.industry, Cancer, Hematology, Middle Aged, medicine.disease, Chemotherapy regimen, Neoadjuvant Therapy, 030104 developmental biology, 030220 oncology & carcinogenesis, Female, Pertuzumab, Fluorouracil, business, medicine.drug
Abstract

The neoadjuvant phase III GeparSepto study showed that substituting nab-paclitaxel for standard solvent-based paclitaxel significantly improved the pathologic complete response (pCR) rate achieved with a sequential neoadjuvant chemotherapy regimen of paclitaxel, epirubicin, and cyclophosphamide for high-risk primary breast cancer. Recent trials demonstrated that in HER2+ breast cancer pCR can be increased by using pertuzumab in addition to trastuzumab and chemotherapy. The present analysis focuses on efficacy and safety data from the subset of patients with HER2+ tumors from the GeparSepto trial (n = 396) in comparison to the HER2- cohort.Patients with histologically confirmed breast cancer (n = 1206) received four cycles of weekly paclitaxel [either solvent-based (Pac) or nab-paclitaxel (nab-Pac), according to randomization] followed by 4 cycles of epirubicin 90 mg/m2 plus cyclophosphamide 600 mg/m2 q3w, with concurrent trastuzumab and pertuzumab q3w for those with HER2+ tumors. The primary endpoint was pCR defined as ypT0 ypN0.Higher rates of pCR were achieved in HER2+ than in HER2- tumors (57.8% versus 22.0%, P 0.0001), with the highest rate in the HER2+/HR- cohort (71.0%; 66.7% Pac, 74.6% nab-Pac). In HER2+/HR+ tumors, the pCR rate was 52.9% (49.7% Pac, 56.4% nab-Pac). Grade ≥3 toxic effects were significantly more common in HER2+ than in HER2- patients, with grade 3-4 diarrhea in 7.6% versus 0.9% (P 0.001) and febrile neutropenia in 6.3% versus 3.3% (P = 0.023) of patients. Left ventricular ejection fraction decreases from baseline were uncommon, with 2.0% versus 0.4% of patients showing decreases to 50% along with a ≥10% decrease from baseline.In HER2+ early breast cancer, a dual HER2-targeted combination of pertuzumab and trastuzumab, together with taxane-epirubicin-cyclophosphamide neoadjuvant chemotherapy, achieved high rates of pCR.

Published
2017

28. 168MO GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status

Author

Link, T., Blohmer, J-U., Just, M., Untch, M., Stötzer, O., Fasching, P.A., Schneeweiss, A., Wimberger, P., Seiler, S., Huober, J., Schmitt, W.D., Jackisch, C., Rhiem, K.E., Hanusch, C., Denkert, C., Sinn, B.V., Engels, K., Nekljudova, V., and Loibl, S.

Published
2020
Full Text
View/download PDF

36. Breast cancer proteomics - differences in protein expression between estrogen receptor-positive and -negative tumors identified by tandem mass tag technology.

Author

Ruckhäberle E, Karn T, Hanker L, Schwarz J, Schulz-Knappe P, Kuhn K, Böhm G, Selzer S, Neukum E, Engels K, Holtrich U, Kaufmann M, and Rody A

Abstract

Background: Proteomic analysis has become an effective tool in breast cancer research. In this study, we applied the new gel-free tandem mass tag (TMT) reference method for the first time in breast cancer. Materials and Methods: Proteomic analysis was used to compare 10 estrogen receptor (ER)-positive and 10 ER-negative samples. The results of the proteomic approach were validated by Western blot, immunohistochemistry and gene expression analysis. Results: 17 proteins with significant differences in expression were identified. 13 proteins were overexpressed in ER-negative tumors and 4 were overexpressed in ER-positive samples. All these proteins were characterized by relatively high cellular abundance. Conclusions: Our results demonstrate that the gel-free TMT approach allows the quantification of differences in protein expression levels. Further improvement of the sensitivity by subfractionation of the tissue should allow also the identification of low-abundance proteins and might lead to the use of this method in breast cancer research. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

37. Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer.

Author

Ruckhäberle, E., Holtrich, U., Engels, K., Hanker, L., Gätje, R., Metzler, D., Karn, T., Kaufmann, M., and Rody, A.

Subjects
CANCER patients, BREAST cancer, CANCER treatment, APOPTOSIS, CELL death
Abstract

Objectives Ceramide and sphingosine mediate response to cancer therapy, inhibit cell growth and induce apoptosis in vitro. Only a few clinical data about the impact of ceramide and sphingosine iny vivo are available. We investigated the relevance of ceramide- and sphingosine-generating enzymes in breast cancer (acid ceramidase 1 (ASAH1), ceramide synthases 4 (LASS4) and 6 (LASS6)) by means of gene expression analysis. Methods We analyzed differences in ASAH1, LASS4 and LASS6 on mRNA level between breast cancer subgroups using microarray data from 1581 tumor samples. Results High ASAH1, LASS4 and LASS6 expression correlates with pathohistological grading ( p < 0.001) and estrogen receptor (ER) status ( p < 0.001). High ASAH1 expression was associated with a larger tumor size >2 cm ( p = 0.003), while high LASS6 expression was correlated with ErbB2 negativity ( p < 0.001). In survival analysis, we detected a significant better prognosis of patients with higher ASAH1 expression ( p = 0.002) in the ER-positive subgroup. In contrast, expression of LASS4 or LASS6 did not show any prognostic impact. In the multivariate analysis, only ASAH1 expression ( p = 0.002), tumor size ( p < 0.0001) and ErbB2 positivity ( p = 0.041) remained significant. Conclusion ASAH1 is an estrogen-dependent member of the sphingolipid metabolism, which might provide further prognostic information in ER-positive breast cancers. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results